title: Unbinding pathways of VEGFR2 inhibitors revealed by steered molecular dynamics.
abstract: A detailed atomistic description of the unbinding process of sorafenib and sunitinib, two known VEGFR2 inhibitors clinically used to treat renal cell carcinoma, was unraveled by using steered molecular dynamics (SMD) simulations. While sunitinib is a fast-dissociating binder, sorafenib exhibits quite a long residence time at this enzyme, which might impact its duration of action in vivo. In order to gain insights into the kinetically different behaviors of the two inhibitors, an SMD study was carried out, which involved a careful optimization of the force and velocity parameters. We were able to identify two different binding pathways for the two inhibitors, as sunitinib exited the ATP binding site from the cavity entrance without a rupture point while sorafenib moved opposite to the ATP binding site entrance. Furthermore, the calculated ΔGoff values clearly reflect on a qualitative level the distinct off-rates of the two inhibitors, thus suggesting that this protocol could be tried on other VEGFR2 ligands to assess its robustness and then used to rank structural analogues of these derivatives.
authors.affiliation: Chemistry Research and Drug Design Department, Chiesi Farmaceutici S.p.A. , Largo F. Belloli 11a, 43122 Parma, Italy.
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Capelli
authors.forename: Gabriele
authors.initials: G
authors.lastname: Costantino
mesh_terms: D020134:Catalytic Domain; D006801:Humans; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology; D056004:Molecular Dynamics Simulation; D047428:Protein Kinase Inhibitors / Q000378:metabolism* / Q000494:pharmacology*; D011758:Pyrroles / Q000378:metabolism / Q000494:pharmacology; D000077210:Sunitinib; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D040301:Vascular Endothelial Growth Factor Receptor-2; D000077210:Sunitinib